Frequency and severity of COVID-19 in patients treated with biological disease-modifying anti-rheumatic drugs for inflammatory rheumatic disease: a cross-sectional study

Clin Exp Rheumatol. 2020 Nov-Dec;38(6):1273. Epub 2020 Nov 22.

Authors

Anne Lohse¹, Marie Bossert¹, Ana-Maria Bozgan¹, Aline Charpentier¹, Cerise Guillochon¹, Charlotte Bourgoin², Jean-Charles Balblanc¹, Thierry Conrozier³

Affiliations

¹ Department of Rheumatology, Nord Franche-Comté Hospital, Belfort, France.
² Clinical Research Unit, Nord Franche-Comté Hospital, Belfort, France.
³ Department of Rheumatology and Clinical Research Unit, Nord Franche-Comté Hospital, Belfort, France. thierry.conrozier@hnfc.fr.

PMID: 33253100

No abstract available

Publication types

Letter

MeSH terms

Antirheumatic Agents* / adverse effects
Biological Products* / therapeutic use
COVID-19*
Cross-Sectional Studies
Humans
Pandemics
Rheumatic Diseases* / drug therapy
Rheumatic Diseases* / epidemiology
SARS-CoV-2

Substances

Antirheumatic Agents
Biological Products